The worst mistake Moderna investors can make right now

The COVID-19 vaccine could be the first of a long list of successes.

| More on:
asx share price growth represented by hand holding hourglass surrounded by dollar signs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

In late 2018, Moderna Inc (NASDAQ: MRNA) went public in the largest biotech initial public offering (IPO) in history. Its value barely moved until mid-February 2020, when COVID-19 cases in the U.S. started showing up in multiple states. Now that its coronavirus vaccine has received Emergency Use Authorization, some investors might think there is limited upside left in the stock. That thinking might lead shareholders of Moderna to do the worst thing they could do right now.

Warp speed and beyond

Working with the National Institute of Allergy and Infectious Diseases, the company delivered a vaccine just 42 days after the genome sequence of the novel coronavirus was made public. Since then, the U.S. government has provided $4.1 billion to the company to get the drug to market, and will purchase 200 million doses of the vaccine with an option to buy 300 million more. Management's base case is for 600 million of the doses to be available by the end of 2021.

Much has been made about using mRNA for its vaccine, but patented fat molecules that deliver the genetic instructions to the cell are also part of the secret sauce. Without these, a strong response from the immune system would destroy both carrier and cargo. On a December investor conference call, CEO Stephane Bancel referenced the 20 products in the company's pipeline using this approach, asserting capital had been a limiting factor in the past. Now, with $4 billion of cash on the balance sheet, he expects more successful launches such as the potential for $2 billion to $5 billion in sales from the company's cytomegalovirus vaccine, which is currently in a phase 2 trial. 

Selling the stock now that one drug is authorized may lock in a profit, but Moderna's most valuable asset could be its platform for drug development. If so, it will take years to play out. Shareholders who sell now could be giving up on the company just as it's starting to revolutionize how diseases are treated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A young entrepreneur boy catching money at his desk, indicating growth in the ASX share price or dividends
International Stock News

Why this high-flying investor is selling Tesla shares and buying this US tech stock instead

Ark Invest funds have been selling the electric vehicle maker's stock over the last few weeks and reinvesting the proceeds…

Read more »

two computer geeks sit across from each other with their laptop computers touching as they look confused and confounded by what they are seeing on their screens.
International Stock News

Is Nvidia stock heading to $175?

The bulls are lining up ahead of Nvidia's earnings report next week.

Read more »

A woman holds a bitcoin token in her hand as she smiles at the camera in the background.
International Stock News

Bitcoin keeps soaring. Could it hit $95,000 this week?

Could the current crypto rally have enough juice to push the coin above that once-inconceivable level?

Read more »

A boy in a green shirt holds up his hands in front of a screen full of question marks.
International Stock News

2 reasons to buy Nvidia shares before November 20 (and 1 reason to wait)

This top AI stock has soared nearly 200% this year!

Read more »

A group of friends push their van up the road on an Australian road.
International Stock News

Why Tesla stock just pulled back

Tesla finally hit a speed bump after a blistering post-election rally.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
International Stock News

Why Tesla stock keeps going up

Tesla stock costs more than $1 trillion now. Is that too expensive?

Read more »

A businessman in soft-focus holds two fingers in the air in the foreground of the shot as he stands smiling in the background against a clear sky.
International Stock News

2 Numbers I'll be looking for on November 20 when Nvidia reports earnings

While many analysts and investors will be looking at revenue and profit growth, two other figures are more important to…

Read more »

A man wearing a blue jumper and a hat looks at his laptop with a distressed and fearful look on his face.
International Stock News

Magnificent Seven: Unstoppable tech stock giants or risky buys?

Did you know the "Magnificent Seven" moniker was meant as a warning, not an endorsement? Check out the risks and…

Read more »